BTIG Research Raises Enovis (NYSE:ENOV) Price Target to $40.00

Enovis (NYSE:ENOV) had its price target upped by equities research analysts at BTIG Research from $39.00 to $40.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential upside of 49.90% from the company’s current price.

ENOV has been the subject of several other research reports. Evercore set a $32.00 price objective on shares of Enovis in a report on Monday, July 6th. UBS Group reissued a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research note on Monday, July 6th. Finally, Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Enovis Stock Performance

Shares of NYSE ENOV opened at $26.68 on Thursday. Enovis has a 12-month low of $19.14 and a 12-month high of $34.28. The company has a market cap of $1.54 billion, a PE ratio of -1.39 and a beta of 1.34. The stock has a 50 day simple moving average of $24.62 and a 200-day simple moving average of $23.97. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the previous year, the business earned $0.79 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts forecast that Enovis will post 3.12 EPS for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 4,200 shares of company stock worth $92,084 over the last quarter. 2.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Enovis

Several large investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in shares of Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after buying an additional 621 shares during the period. MGO One Seven LLC increased its holdings in shares of Enovis by 9.4% in the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after buying an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. Empowered Funds LLC raised its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. Finally, Inscription Capital LLC grew its holdings in shares of Enovis by 9.4% during the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after buying an additional 1,016 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
• Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
• Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
• Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.